These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 26292198)
1. Progression of anemia and its relationship with renal function, blood pressure, and erythropoietin in rats with chronic kidney disease. Phillips JK; Boyd R; Krockenberger MB; Burgio G Vet Clin Pathol; 2015 Sep; 44(3):342-54. PubMed ID: 26292198 [TBL] [Abstract][Full Text] [Related]
2. Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease. Jeewandara TM; Ameer OZ; Boyd R; Wyse BF; Underwood CF; Phillips JK Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):353-60. PubMed ID: 25676668 [TBL] [Abstract][Full Text] [Related]
3. Chronic treatment with tempol does not significantly ameliorate renal tissue hypoxia or disease progression in a rodent model of polycystic kidney disease. Ding A; Kalaignanasundaram P; Ricardo SD; Abdelkader A; Witting PK; Broughton BR; Kim HB; Wyse BF; Phillips JK; Evans RG Clin Exp Pharmacol Physiol; 2012 Nov; 39(11):917-29. PubMed ID: 23006058 [TBL] [Abstract][Full Text] [Related]
4. Abnormal central control underlies impaired baroreflex control of heart rate and sympathetic nerve activity in female Lewis polycystic kidney rats. Salman IM; Phillips JK; Ameer OZ; Hildreth CM J Hypertens; 2015 Jul; 33(7):1418-28. PubMed ID: 26039532 [TBL] [Abstract][Full Text] [Related]
5. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia. Landau D; London L; Bandach I; Segev Y PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538 [TBL] [Abstract][Full Text] [Related]
6. Temporal development of baroreceptor dysfunction in a rodent model of chronic kidney disease. Hildreth CM; Kandukuri DS; Goodchild AK; Phillips JK Clin Exp Pharmacol Physiol; 2013 Jul; 40(7):458-65. PubMed ID: 23662737 [TBL] [Abstract][Full Text] [Related]
7. Down-Regulation of Cardiac Erythropoietin Receptor and its Downstream Activated Signal Transducer Phospho-STAT-5 in a Rat Model of Chronic Kidney Disease. Hertzberg-Bigelman E; Barashi R; Levy R; Cohen L; Ben-Shoshan J; Keren G; Entin-Meer M Isr Med Assoc J; 2016 Jun; 18(6):326-30. PubMed ID: 27468524 [TBL] [Abstract][Full Text] [Related]
8. Increased water intake reduces long-term renal and cardiovascular disease progression in experimental polycystic kidney disease. Sagar PS; Zhang J; Luciuk M; Mannix C; Wong ATY; Rangan GK PLoS One; 2019; 14(1):e0209186. PubMed ID: 30601830 [TBL] [Abstract][Full Text] [Related]
9. Renal Function and Hematology in Rats with Congenital Renal Hypoplasia. Yasuda H; Amakasu K; Tochigi Y; Katayama K; Suzuki H Comp Med; 2016 Feb; 66(1):10-20. PubMed ID: 26884405 [TBL] [Abstract][Full Text] [Related]
10. Effects of cisplatin on erythropoietin production in rats. Unami A; Nishina N; Terai T; Sato S; Tamura T; Noda K; Mine Y J Toxicol Sci; 1996 Aug; 21(3):157-65. PubMed ID: 8887884 [TBL] [Abstract][Full Text] [Related]
11. Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease. Phillips JK; Hopwood D; Loxley RA; Ghatora K; Coombes JD; Tan YS; Harrison JL; McKitrick DJ; Holobotvskyy V; Arnolda LF; Rangan GK Kidney Blood Press Res; 2007; 30(3):129-44. PubMed ID: 17446713 [TBL] [Abstract][Full Text] [Related]
12. Impact of prenatal and postnatal maternal environment on nephron endowment, renal function and blood pressure in the Lewis polycystic kidney rat. Ding A; Walton SL; Moritz KM; Phillips JK J Dev Orig Health Dis; 2019 Apr; 10(2):154-163. PubMed ID: 30274564 [TBL] [Abstract][Full Text] [Related]
13. Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: a prospective cohort study. Fujita Y; Doi Y; Hamano T; Hatazaki M; Umayahara Y; Isaka Y; Tsubakihara Y Sci Rep; 2019 Oct; 9(1):14871. PubMed ID: 31619722 [TBL] [Abstract][Full Text] [Related]
14. Effects of recombinant human erythropoietin on blood pressure and renal function in SHR with chronic renal failure. Kohzuki M; Yasujima M; Kanazawa M; Yoshida K; Sato T; Abe K Clin Exp Pharmacol Physiol Suppl; 1995 Dec; 22(1):S165-6. PubMed ID: 9072339 [TBL] [Abstract][Full Text] [Related]
15. Chronic kidney disease impairs renal nerve and haemodynamic reflex responses to vagal afferent input through a central mechanism. Salman IM; Hildreth CM; Phillips JK Auton Neurosci; 2017 May; 204():65-73. PubMed ID: 27776979 [TBL] [Abstract][Full Text] [Related]
16. Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure. Teixeira AM; Garrido P; Santos P; Alves R; Parada B; Costa E; Almeida A; Teixeira-Lemos E; Sereno J; Pinto R; Belo L; Santos-Silva A; Teixeira F; Reis F Ren Fail; 2010; 32(9):1073-80. PubMed ID: 20863212 [TBL] [Abstract][Full Text] [Related]
17. Long-Term Angiotensin II Receptor Blockade Limits Hypertension, Aortic Dysfunction, and Structural Remodeling in a Rat Model of Chronic Kidney Disease. Ameer OZ; Butlin M; Kaschina E; Sommerfeld M; Avolio AP; Phillips JK J Vasc Res; 2016; 53(3-4):216-229. PubMed ID: 27880955 [TBL] [Abstract][Full Text] [Related]
18. AT1 Receptor Antagonism Improves Structural, Functional, and Biomechanical Properties in Resistance Arteries in a Rodent Chronic Kidney Disease Model. Quek KJ; Ameer OZ; Phillips JK Am J Hypertens; 2018 May; 31(6):696-705. PubMed ID: 29425281 [TBL] [Abstract][Full Text] [Related]
19. Effect of dimethyl fumarate on renal disease progression in a genetic ortholog of nephronophthisis. Oey O; Rao P; Luciuk M; Mannix C; Rogers NM; Sagar P; Wong A; Rangan G Exp Biol Med (Maywood); 2018 Mar; 243(5):428-436. PubMed ID: 29436846 [TBL] [Abstract][Full Text] [Related]
20. Progressive vascular remodelling, endothelial dysfunction and stiffness in mesenteric resistance arteries in a rodent model of chronic kidney disease. Quek KJ; Boyd R; Ameer OZ; Zangerl B; Butlin M; Murphy TV; Avolio AP; Phillips JK Vascul Pharmacol; 2016 Jun; 81():42-52. PubMed ID: 26771067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]